Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

By M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastié, C. Schvartz and 10 more. New England Journal of Medicine, 2012

611 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Radiology, Nuclear Medicine and Imaging, Surgery

View Paper: https://www.semanticscholar.org/paper/d39d0e5ed1bdfd52ddc6e587d8b19309cc15aa95

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Luster
2. Sebastiano Filetti
3. G. Francis
4. S. Waguespack
5. D. Hartl
6. C. Durante
7. S. Leboulleux
8. P. Angelos

Citations in the corpus

• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, neutral): “The rate of successful remnant ablation was reported to be not inferior using an administered activity of 30 mCi as compared to 100 mCi in three trials after preparation with thyroid hormone withdrawal (699,701,714) and in two trials after preparation with rhTSH (699,701), including data from the tw”
• Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer (2015, background): “The use of rhTSH has not been shown to decrease salivary gland toxicity compared to thyroid hormone withdrawal (260); however, lacrimal dysfunction (watery eyes) was more frequent in patients undergoing thyroid hormone withdrawal (261).”
• Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “7 GBq) following levothyroxine withdrawal are equally likely to produce successful ablation [I, A] [47, 48].”